News & Analysis as of

Weight-Loss Products Life Sciences

Blank Rome LLP

Novo Nordisk Files Patent Infringement Suit Involving Compounded Semaglutide Products

Blank Rome LLP on

Novo Nordisk filed suit in the U.S. District Court for the District of Delaware on February 9, 2026, alleging that compounded semaglutide injections and pills infringe on its patent covering the active pharmaceutical...more

American Conference Institute (ACI)

[Virtual Conference] Inaugural Summit on GLP-1 Law & Policy - July 24th, 8:15 am - 5:15 pm ET

The $100B+ Weight-Loss Drug Market Is Red Hot—But So Are the Legal, Regulatory, and Compliance Risks. As the GLP-1 revolution reshapes the future of metabolic health, life sciences companies face mounting scrutiny from...more

Dentons

Ep. 4 - Ozempic, Wegovy, and the New Compliance Risks for Providers

Dentons on

Diabetes and obesity drugs have skyrocketed in popularity as of late. According to a report released by Trilliant Health in September 2023, healthcare providers in the United States wrote more than 9 million prescriptions for...more

Console and Associates, P.C.

Patients Report Stomach Paralysis and Other Serious Side Effects After Taking Popular Weight-Loss Drugs Ozempic and Wegovy

Are you a diabetes patient who took Ozempic? Did you take Wegovy in hopes of losing weight? Have you suffered life-changing gastrointestinal issues since you’ve been taking Ozempic or Wegovy? If so, you are not alone....more

4 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide